In vivo angiogenesis induced by recombinant adenovirus vectors coding either for secreted or nonsecreted forms of acidic fibroblast growth factor

Judith Mühlhauser, Roberto Pili, Marsha J. Merrill, Hiroyuki Maeda, Antonino Passaniti, Ronald G. Crystal, Maurizio C. Capogrossi

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

In vivo gene transfer of angiogenic growth factors represents a potential approach to the treatment of ischemic diseases. The present study examined the in vitro and in vivo effects of two replication-deficient recombinant adenovirus (Ad) vectors coding for human acidic fibroblast growth factor (aFGF1-154). One vector codes for the nonsecreted form of the peptide (AdCMV.aFGF1-154), and the other vector codes for a recombinant, secreted form (AdCMV.sp+aFGF1-154). AdCMV.NLSβgal, an adenovirus vector coding for β-galactosidase (β-Gal), was used as a control. Assessment of proliferation of starved human umbilical vein endothelial cells infected with AdCMV.aFGF1-154 and AdCMV.sp+aFGF1-154 (20 pfu/cell) showed approximately 6- and 10-fold increase in cell number over control, respectively. Infection with AdCMV.sp+aFGF1-154 and with AdCMV.aFGF1-154 enhanced endothelial cell differentiation into capillary-like structures in vitro. However, this effect was significantly more pronounced with AdCMV.sp+aFGF1-154 than with AdCMV.aFGF1-154. Angiogenesis in vivo was assessed by injecting subcutaneously into mice 750 μl of reconstituted basement membrane proteins (Matrigel) and the Ad vectors (2 x 108 pfu). After 14 days, there was histologic evidence of neovascularization in the animal's tissue surrounding the Matrigel plugs with AdCMV.aFGP1-154 and AdCMV.sp+aFGF1-154. Further, the hemoglobin content of the Matrigel plugs with AdCMV.aFGF1-154 and with AdCMV.sp+aFGF1-154 was, respectively, 2.3- and 2.6-fold higher than with AdCMV.NLSβgal. Together, these observations support the concept that adenovirus vectors coding for various forms of acidic FGF1-154 may be used to induce angiogenesis in vivo and may provide a new therapeutic approach to ischemic diseases.

Original languageEnglish (US)
Pages (from-to)1457-1465
Number of pages9
JournalHuman Gene Therapy
Volume6
Issue number11
StatePublished - Nov 1995
Externally publishedYes

Fingerprint

Fibroblast Growth Factor 1
Adenoviridae
Galactosidases
Angiogenesis Inducing Agents
Human Umbilical Vein Endothelial Cells
Basement Membrane
Cell Differentiation
Intercellular Signaling Peptides and Proteins
Membrane Proteins
Hemoglobins
Endothelial Cells
Cell Count
Peptides
Infection
Genes
matrigel
In Vitro Techniques
Therapeutics

ASJC Scopus subject areas

  • Genetics

Cite this

Mühlhauser, J., Pili, R., Merrill, M. J., Maeda, H., Passaniti, A., Crystal, R. G., & Capogrossi, M. C. (1995). In vivo angiogenesis induced by recombinant adenovirus vectors coding either for secreted or nonsecreted forms of acidic fibroblast growth factor. Human Gene Therapy, 6(11), 1457-1465.

In vivo angiogenesis induced by recombinant adenovirus vectors coding either for secreted or nonsecreted forms of acidic fibroblast growth factor. / Mühlhauser, Judith; Pili, Roberto; Merrill, Marsha J.; Maeda, Hiroyuki; Passaniti, Antonino; Crystal, Ronald G.; Capogrossi, Maurizio C.

In: Human Gene Therapy, Vol. 6, No. 11, 11.1995, p. 1457-1465.

Research output: Contribution to journalArticle

Mühlhauser, J, Pili, R, Merrill, MJ, Maeda, H, Passaniti, A, Crystal, RG & Capogrossi, MC 1995, 'In vivo angiogenesis induced by recombinant adenovirus vectors coding either for secreted or nonsecreted forms of acidic fibroblast growth factor', Human Gene Therapy, vol. 6, no. 11, pp. 1457-1465.
Mühlhauser, Judith ; Pili, Roberto ; Merrill, Marsha J. ; Maeda, Hiroyuki ; Passaniti, Antonino ; Crystal, Ronald G. ; Capogrossi, Maurizio C. / In vivo angiogenesis induced by recombinant adenovirus vectors coding either for secreted or nonsecreted forms of acidic fibroblast growth factor. In: Human Gene Therapy. 1995 ; Vol. 6, No. 11. pp. 1457-1465.
@article{bad0187046e14cc98c728688f33dac67,
title = "In vivo angiogenesis induced by recombinant adenovirus vectors coding either for secreted or nonsecreted forms of acidic fibroblast growth factor",
abstract = "In vivo gene transfer of angiogenic growth factors represents a potential approach to the treatment of ischemic diseases. The present study examined the in vitro and in vivo effects of two replication-deficient recombinant adenovirus (Ad) vectors coding for human acidic fibroblast growth factor (aFGF1-154). One vector codes for the nonsecreted form of the peptide (AdCMV.aFGF1-154), and the other vector codes for a recombinant, secreted form (AdCMV.sp+aFGF1-154). AdCMV.NLSβgal, an adenovirus vector coding for β-galactosidase (β-Gal), was used as a control. Assessment of proliferation of starved human umbilical vein endothelial cells infected with AdCMV.aFGF1-154 and AdCMV.sp+aFGF1-154 (20 pfu/cell) showed approximately 6- and 10-fold increase in cell number over control, respectively. Infection with AdCMV.sp+aFGF1-154 and with AdCMV.aFGF1-154 enhanced endothelial cell differentiation into capillary-like structures in vitro. However, this effect was significantly more pronounced with AdCMV.sp+aFGF1-154 than with AdCMV.aFGF1-154. Angiogenesis in vivo was assessed by injecting subcutaneously into mice 750 μl of reconstituted basement membrane proteins (Matrigel) and the Ad vectors (2 x 108 pfu). After 14 days, there was histologic evidence of neovascularization in the animal's tissue surrounding the Matrigel plugs with AdCMV.aFGP1-154 and AdCMV.sp+aFGF1-154. Further, the hemoglobin content of the Matrigel plugs with AdCMV.aFGF1-154 and with AdCMV.sp+aFGF1-154 was, respectively, 2.3- and 2.6-fold higher than with AdCMV.NLSβgal. Together, these observations support the concept that adenovirus vectors coding for various forms of acidic FGF1-154 may be used to induce angiogenesis in vivo and may provide a new therapeutic approach to ischemic diseases.",
author = "Judith M{\"u}hlhauser and Roberto Pili and Merrill, {Marsha J.} and Hiroyuki Maeda and Antonino Passaniti and Crystal, {Ronald G.} and Capogrossi, {Maurizio C.}",
year = "1995",
month = "11",
language = "English (US)",
volume = "6",
pages = "1457--1465",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "11",

}

TY - JOUR

T1 - In vivo angiogenesis induced by recombinant adenovirus vectors coding either for secreted or nonsecreted forms of acidic fibroblast growth factor

AU - Mühlhauser, Judith

AU - Pili, Roberto

AU - Merrill, Marsha J.

AU - Maeda, Hiroyuki

AU - Passaniti, Antonino

AU - Crystal, Ronald G.

AU - Capogrossi, Maurizio C.

PY - 1995/11

Y1 - 1995/11

N2 - In vivo gene transfer of angiogenic growth factors represents a potential approach to the treatment of ischemic diseases. The present study examined the in vitro and in vivo effects of two replication-deficient recombinant adenovirus (Ad) vectors coding for human acidic fibroblast growth factor (aFGF1-154). One vector codes for the nonsecreted form of the peptide (AdCMV.aFGF1-154), and the other vector codes for a recombinant, secreted form (AdCMV.sp+aFGF1-154). AdCMV.NLSβgal, an adenovirus vector coding for β-galactosidase (β-Gal), was used as a control. Assessment of proliferation of starved human umbilical vein endothelial cells infected with AdCMV.aFGF1-154 and AdCMV.sp+aFGF1-154 (20 pfu/cell) showed approximately 6- and 10-fold increase in cell number over control, respectively. Infection with AdCMV.sp+aFGF1-154 and with AdCMV.aFGF1-154 enhanced endothelial cell differentiation into capillary-like structures in vitro. However, this effect was significantly more pronounced with AdCMV.sp+aFGF1-154 than with AdCMV.aFGF1-154. Angiogenesis in vivo was assessed by injecting subcutaneously into mice 750 μl of reconstituted basement membrane proteins (Matrigel) and the Ad vectors (2 x 108 pfu). After 14 days, there was histologic evidence of neovascularization in the animal's tissue surrounding the Matrigel plugs with AdCMV.aFGP1-154 and AdCMV.sp+aFGF1-154. Further, the hemoglobin content of the Matrigel plugs with AdCMV.aFGF1-154 and with AdCMV.sp+aFGF1-154 was, respectively, 2.3- and 2.6-fold higher than with AdCMV.NLSβgal. Together, these observations support the concept that adenovirus vectors coding for various forms of acidic FGF1-154 may be used to induce angiogenesis in vivo and may provide a new therapeutic approach to ischemic diseases.

AB - In vivo gene transfer of angiogenic growth factors represents a potential approach to the treatment of ischemic diseases. The present study examined the in vitro and in vivo effects of two replication-deficient recombinant adenovirus (Ad) vectors coding for human acidic fibroblast growth factor (aFGF1-154). One vector codes for the nonsecreted form of the peptide (AdCMV.aFGF1-154), and the other vector codes for a recombinant, secreted form (AdCMV.sp+aFGF1-154). AdCMV.NLSβgal, an adenovirus vector coding for β-galactosidase (β-Gal), was used as a control. Assessment of proliferation of starved human umbilical vein endothelial cells infected with AdCMV.aFGF1-154 and AdCMV.sp+aFGF1-154 (20 pfu/cell) showed approximately 6- and 10-fold increase in cell number over control, respectively. Infection with AdCMV.sp+aFGF1-154 and with AdCMV.aFGF1-154 enhanced endothelial cell differentiation into capillary-like structures in vitro. However, this effect was significantly more pronounced with AdCMV.sp+aFGF1-154 than with AdCMV.aFGF1-154. Angiogenesis in vivo was assessed by injecting subcutaneously into mice 750 μl of reconstituted basement membrane proteins (Matrigel) and the Ad vectors (2 x 108 pfu). After 14 days, there was histologic evidence of neovascularization in the animal's tissue surrounding the Matrigel plugs with AdCMV.aFGP1-154 and AdCMV.sp+aFGF1-154. Further, the hemoglobin content of the Matrigel plugs with AdCMV.aFGF1-154 and with AdCMV.sp+aFGF1-154 was, respectively, 2.3- and 2.6-fold higher than with AdCMV.NLSβgal. Together, these observations support the concept that adenovirus vectors coding for various forms of acidic FGF1-154 may be used to induce angiogenesis in vivo and may provide a new therapeutic approach to ischemic diseases.

UR - http://www.scopus.com/inward/record.url?scp=0028864850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028864850&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 1457

EP - 1465

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 11

ER -